(Q51366906)

English

Pioglitazone improves the cardiovascular profile in patients with uncomplicated systemic lupus erythematosus: a double-blind randomized clinical trial.

scientific article published on 12 October 2011

In more languages

default values for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

4 April 2018

http://europepmc.org/abstract/MED/21993383

Pioglitazone improves the cardiovascular profile in patients with uncomplicated systemic lupus erythematosus: a double-blind randomized clinical trial. (English)

1 reference

Europe PubMed Central

PubMed publication ID

4 April 2018

http://europepmc.org/abstract/MED/21993383

systemic lupus erythematosus

1 reference

based on heuristic

inferred from title

author name string

J G Juárez-Rojas

1

1 reference

Europe PubMed Central

PubMed publication ID

4 April 2018

http://europepmc.org/abstract/MED/21993383

A X Medina-Urrutia

2

1 reference

Europe PubMed Central

PubMed publication ID

4 April 2018

http://europepmc.org/abstract/MED/21993383

E Jorge-Galarza

3

1 reference

Europe PubMed Central

PubMed publication ID

4 April 2018

http://europepmc.org/abstract/MED/21993383

N A Caracas-Portilla

4

1 reference

Europe PubMed Central

PubMed publication ID

4 April 2018

http://europepmc.org/abstract/MED/21993383

R Posadas-Sánchez

5

1 reference

Europe PubMed Central

PubMed publication ID

4 April 2018

http://europepmc.org/abstract/MED/21993383

G C Cardoso-Saldaña

6

1 reference

Europe PubMed Central

PubMed publication ID

4 April 2018

http://europepmc.org/abstract/MED/21993383

M V Goycochea-Robles

7

1 reference

Europe PubMed Central

PubMed publication ID

4 April 2018

http://europepmc.org/abstract/MED/21993383

L H Silveira

8

1 reference

Europe PubMed Central

PubMed publication ID

4 April 2018

http://europepmc.org/abstract/MED/21993383

L Lino-Pérez

9

1 reference

Europe PubMed Central

PubMed publication ID

4 April 2018

http://europepmc.org/abstract/MED/21993383

J Mas-Oliva

10

1 reference

Europe PubMed Central

PubMed publication ID

4 April 2018

http://europepmc.org/abstract/MED/21993383

O Pérez-Méndez

11

1 reference

Europe PubMed Central

PubMed publication ID

4 April 2018

http://europepmc.org/abstract/MED/21993383

C Posadas-Romero

12

1 reference

Europe PubMed Central

PubMed publication ID

4 April 2018

http://europepmc.org/abstract/MED/21993383

publication date

12 October 2011

1 reference

Europe PubMed Central

PubMed publication ID

4 April 2018

http://europepmc.org/abstract/MED/21993383

1 reference

Europe PubMed Central

PubMed publication ID

4 April 2018

http://europepmc.org/abstract/MED/21993383

21

1 reference

Europe PubMed Central

PubMed publication ID

4 April 2018

http://europepmc.org/abstract/MED/21993383

1

1 reference

Europe PubMed Central

PubMed publication ID

4 April 2018

http://europepmc.org/abstract/MED/21993383

27-35

1 reference

Europe PubMed Central

PubMed publication ID

4 April 2018

http://europepmc.org/abstract/MED/21993383

Epidemiology of atherosclerosis in systemic lupus erythematosus

1 reference

https://api.crossref.org/works/10.1177%2F0961203311422096

21 January 2018

Risk factors for cardiovascular disease in systemic lupus erythematosus

1 reference

https://api.crossref.org/works/10.1177%2F0961203311422096

21 January 2018

High insulin levels and increased low-density lipoprotein oxidizability in pediatric patients with systemic lupus erythematosus.

1 reference

https://api.crossref.org/works/10.1177%2F0961203311422096

21 January 2018

Effects of inflammation on cholesterol metabolism: impact on systemic lupus erythematosus.

1 reference

https://api.crossref.org/works/10.1177%2F0961203311422096

21 January 2018

High-density lipoproteins are abnormal in young women with uncomplicated systemic lupus erythematosus

1 reference

https://api.crossref.org/works/10.1177%2F0961203311422096

21 January 2018

Lipoprotein subclasses and particle size determined by nuclear magnetic resonance spectroscopy in systemic lupus erythematosus

1 reference

https://api.crossref.org/works/10.1177%2F0961203311422096

21 January 2018

Proinflammatory high-density lipoprotein as a biomarker for atherosclerosis in patients with systemic lupus erythematosus and rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1177%2F0961203311422096

21 January 2018

Dysfunctional proinflammatory high-density lipoproteins confer increased risk of atherosclerosis in women with systemic lupus erythematosus

1 reference

https://api.crossref.org/works/10.1177%2F0961203311422096

21 January 2018

Inflammation in atherosclerosis

1 reference

https://api.crossref.org/works/10.1177%2F0961203311422096

21 January 2018

Value of high-density lipoprotein (HDL) subpopulations in predicting recurrent cardiovascular events in the Veterans Affairs HDL Intervention Trial

1 reference

https://api.crossref.org/works/10.1177%2F0961203311422096

21 January 2018

The peroxisome proliferator-activated receptor gamma agonist pioglitazone improves cardiometabolic risk and renal inflammation in murine lupus.

1 reference

https://api.crossref.org/works/10.1177%2F0961203311422096

21 January 2018

Functionally defective high-density lipoprotein: a new therapeutic target at the crossroads of dyslipidemia, inflammation, and atherosclerosis

1 reference

https://api.crossref.org/works/10.1177%2F0961203311422096

21 January 2018

Metabolic syndrome is associated with elevated oxidative stress and dysfunctional dense high-density lipoprotein particles displaying impaired antioxidative activity

1 reference

https://api.crossref.org/works/10.1177%2F0961203311422096

21 January 2018

A normotriglyceridemic, low HDL-cholesterol phenotype is characterised by elevated oxidative stress and HDL particles with attenuated antioxidative activity.

1 reference

https://api.crossref.org/works/10.1177%2F0961203311422096

21 January 2018

Elevated soluble cellular adhesion molecules in subjects with low HDL-cholesterol.

1 reference

https://api.crossref.org/works/10.1177%2F0961203311422096

21 January 2018

Pioglitazone and mechanisms of CV protection

1 reference

https://api.crossref.org/works/10.1177%2F0961203311422096

21 January 2018

The impact of pioglitazone on glycemic control and atherogenic dyslipidemia in patients with type 2 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1177%2F0961203311422096

21 January 2018

Effects of pioglitazone on lipoproteins, inflammatory markers, and adipokines in nondiabetic patients with metabolic syndrome

1 reference

https://api.crossref.org/works/10.1177%2F0961203311422096

21 January 2018

Combining beta-adrenergic and peroxisome proliferator-activated receptor gamma stimulation improves lipoprotein composition in healthy moderately obese subjects

1 reference

https://api.crossref.org/works/10.1177%2F0961203311422096

21 January 2018

The 1982 revised criteria for the classification of systemic lupus erythematosus

1 reference

https://api.crossref.org/works/10.1177%2F0961203311422096

21 January 2018

Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; Internat

1 reference

https://api.crossref.org/works/10.1177%2F0961203311422096

21 January 2018

A comparison of methods for the estimation of plasma low- and very low-density lipoprotein cholesterol. The Lipid Research Clinics Prevalence Study.

1 reference

https://api.crossref.org/works/10.1177%2F0961203311422096

21 January 2018

Homeostasis model assessment: insulin resistance and ?-cell function from fasting plasma glucose and insulin concentrations in man

1 reference

https://api.crossref.org/works/10.1177%2F0961203311422096

21 January 2018

Elevation of fasting insulin and its association with cardiovascular disease risk in women with systemic lupus erythematosus

1 reference

https://api.crossref.org/works/10.1177%2F0961203311422096

21 January 2018

Improvement of cardiovascular risk markers by pioglitazone is independent from glycemic control: results from the pioneer study

1 reference

https://api.crossref.org/works/10.1177%2F0961203311422096

21 January 2018

Serum amyloid A, the major vertebrate acute-phase reactant

1 reference

https://api.crossref.org/works/10.1177%2F0961203311422096

21 January 2018

Acute-phase proteins and other systemic responses to inflammation

1 reference

https://api.crossref.org/works/10.1177%2F0961203311422096

21 January 2018

Serum amyloid A (SAA): a concise review of biology, assay methods and clinical usefulness

1 reference

https://api.crossref.org/works/10.1177%2F0961203311422096

21 January 2018

Plasma concentration of interleukin-6 and the risk of future myocardial infarction among apparently healthy men.

1 reference

https://api.crossref.org/works/10.1177%2F0961203311422096

21 January 2018

Rapid effects of rosiglitazone treatment on endothelial function and inflammatory biomarkers

1 reference

https://api.crossref.org/works/10.1177%2F0961203311422096

21 January 2018

Troglitazone reduces hyperglycaemia and selectively acute-phase serum proteins in patients with Type II diabetes.

1 reference

https://api.crossref.org/works/10.1177%2F0961203311422096

21 January 2018

Pioglitazone has anti-inflammatory effects in patients with Type 2 diabetes.

1 reference

https://api.crossref.org/works/10.1177%2F0961203311422096

21 January 2018

Systemic lupus erythematosus in a multiethnic US cohort (LUMINA). XXIII. Baseline predictors of vascular events.

1 reference

https://api.crossref.org/works/10.1177%2F0961203311422096

21 January 2018

Predictors of the first cardiovascular event in patients with systemic lupus erythematosus - a prospective cohort study

1 reference

https://api.crossref.org/works/10.1177%2F0961203311422096

21 January 2018

High prevalence of the metabolic syndrome in patients with systemic lupus erythematosus: association with disease characteristics and cardiovascular risk factors

1 reference

https://api.crossref.org/works/10.1177%2F0961203311422096

21 January 2018

Conditional disruption of the peroxisome proliferator-activated receptor gamma gene in mice results in lowered expression of ABCA1, ABCG1, and apoE in macrophages and reduced cholesterol efflux.

1 reference

https://api.crossref.org/works/10.1177%2F0961203311422096

21 January 2018

Activation of peroxisome proliferator-activated receptor gamma and retinoid X receptor results in net depletion of cellular cholesteryl esters in macrophages exposed to oxidized lipoproteins

1 reference

https://api.crossref.org/works/10.1177%2F0961203311422096

21 January 2018

High-density lipoprotein subpopulation profile and coronary heart disease prevalence in male participants of the Framingham Offspring Study

1 reference

https://api.crossref.org/works/10.1177%2F0961203311422096

21 January 2018

Insulin Resistance and Atherosclerosis

1 reference

https://api.crossref.org/works/10.1177%2F0961203311422096

21 January 2018

Identifiers

10.1177/0961203311422096

1 reference

Europe PubMed Central

PubMed publication ID

4 April 2018

http://europepmc.org/abstract/MED/21993383

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

4 April 2018

http://europepmc.org/abstract/MED/21993383

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q51366906&oldid=1967446419"